|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/155 | (2006.01) |
| A61K 31/341 | (2006.01) | ||
| A61P 3/10 | (2006.01) | ||
| A61K 31/522 | (2006.01) | ||
| A61K 31/7048 | (2006.01) |
| (11) | Number of the document | 2395983 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10703288.0 |
| Date of filing the European patent application | 2010-02-11 | |
| (97) | Date of publication of the European application | 2011-12-21 |
| (45) | Date of publication and mention of the grant of the patent | 2020-04-08 |
| (46) | Date of publication of the claims translation | 2020-07-10 |
| (86) | Number | PCT/EP2010/051736 |
| Date | 2010-02-11 |
| (87) | Number | WO 2010/092125 |
| Date | 2010-08-19 |
| (30) | Number | Date | Country code |
| 152302 P | 2009-02-13 | US |
| (72) |
EICKELMANN, Peter, DE
MARK,Michael, DE
SEMAN, Leo John, US
THOMAS, Leo, DE
BROEDL, Uli, DE
GREMPLER, Rolf, DE
|
| (73) |
Boehringer Ingelheim International GmbH,
Binger Strasse 173, 55216 Ingelheim am Rhein,
DE
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Farmacinė kompozicija, apimanti SGLT2 inhibitorių, DPP-IV inhibitorių ir, pasirinktinai, papildomą priešdiabetinį agentą, bei jos panaudojimas |
| PHARMACEUTICAL COMPOSITION COMPRISNG A SGLT2 INHIBITOR, A DPP-IV INHIBITOR AND OPTIONALLY A FURTHER ANTIDIABETIC AGENT AND USES THEREOF |
| Payment date | Validity (years) | Amount | |
| 2025-01-23 | 16 | 347.00 EUR |
| 2026-02-11 |